Ergomed Inkomsten in het verleden

Verleden criteriumcontroles 3/6

Ergomed is de winst gegroeid met een gemiddeld jaarlijks percentage van 52.7%, terwijl de Life Sciences industrie de winst jaarlijks groeide met 13.9%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 23.1% per jaar. Het rendement op eigen vermogen van Ergomed is 16.5%, en het heeft een nettomarge van 9.9%.

Belangrijke informatie

52.7%

Groei van de winst

52.7%

Groei van de winst per aandeel

Life Sciences Groei van de industrie	36.9%
Inkomstengroei	23.1%
Rendement op eigen vermogen	16.5%
Nettomarge	9.9%
Laatste winstupdate	30 Jun 2023

Recente prestatie-updates uit het verleden

Recent updates

If You Had Bought Ergomed (LON:ERGO) Stock Five Years Ago, You Could Pocket A 643% Gain Today

Feb 22

Has Ergomed plc's (LON:ERGO) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Jan 18

Ergomed plc's (LON:ERGO) Intrinsic Value Is Potentially 20% Below Its Share Price

Dec 13

We Think Ergomed's (LON:ERGO) Statutory Profit Might Understate Its Earnings Potential

Nov 23

Opbrengsten en kosten

Hoe Ergomed geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

AIM:ERGO Opbrengsten, kosten en inkomsten (GBP Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 23	152	15	40	0
31 Mar 23	149	15	38	0
31 Dec 22	145	15	37	0
30 Sep 22	139	14	35	0
30 Jun 22	132	13	32	0
31 Mar 22	126	13	31	0
31 Dec 21	119	13	29	0
30 Sep 21	110	12	29	0
30 Jun 21	102	12	28	0
31 Mar 21	94	11	27	0
31 Dec 20	86	10	26	0
30 Sep 20	80	8	24	0
30 Jun 20	73	6	23	0
31 Mar 20	71	6	21	0
31 Dec 19	68	6	20	1
30 Sep 19	66	1	19	1
30 Jun 19	64	-3	18	1
31 Mar 19	59	-6	18	1
31 Dec 18	54	-9	17	2
30 Sep 18	54	-8	17	2
30 Jun 18	54	-8	16	2
31 Mar 18	51	-6	15	3
31 Dec 17	48	-5	14	3
30 Sep 17	42	-2	13	2
30 Jun 17	36	0	12	2
31 Mar 17	33	0	11	2
31 Dec 16	29	0	9	1
30 Sep 16	31	1	8	1
30 Jun 16	28	1	7	0
31 Mar 16	29	1	6	0
31 Dec 15	30	2	5	0
30 Sep 15	29	1	6	0
30 Jun 15	28	1	6	0
31 Mar 15	24	1	5	0
31 Dec 14	21	1	4	0
30 Sep 14	19	1	4	0
30 Jun 14	16	1	3	0
31 Mar 14	16	1	3	0
31 Dec 13	15	2	3	0
31 Dec 12	15	0	3	0

Kwaliteitswinsten: ERGO heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (9.9%) ERGO } zijn lager dan vorig jaar (10.1%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: ERGO is de afgelopen 5 jaar winstgevend geworden en heeft de winst met 52.7% per jaar laten groeien.

Versnelling van de groei: De winstgroei van ERGO over het afgelopen jaar ( 12.3% ) ligt onder het 5-jarig gemiddelde ( 52.7% per jaar).

Winst versus industrie: De winstgroei ERGO over het afgelopen jaar ( 12.3% ) overtrof de Life Sciences -sector 5.4%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 16.5% ) van ERGO wordt als laag beschouwd.

Ergomed Inkomsten in het verleden

Verleden criteriumcontroles 3/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Ergomed plc to Report Q2, 2023 Results on Sep 26, 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ergomed plc to Report Fiscal Year 2022 Results on Mar 21, 2023

First half 2022 earnings released: EPS: UK£0.15 (vs UK£0.14 in 1H 2021)

Ergomed plc to Report First Half, 2022 Results on Sep 27, 2022

Recent updates

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Permira Advisers Ltd. completed the acquisition of Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others.

Ergomed Confirms Expected Scheme Timetable

Ergomed plc (AIM:ERGO) acquired Panacea Pharma Projects Limited from Stuart Colligon.

Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others for approximately £700 million.

Ergomed plc to Report Q2, 2023 Results on Sep 26, 2023

Now 20% undervalued after recent price drop

Is It Time To Consider Buying Ergomed plc (LON:ERGO)?

Ergomed plc Provides Earnings Forecast for the Full Year 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ergomed plc, Annual General Meeting, Jun 22, 2023

At UK£9.74, Is Ergomed plc (LON:ERGO) Worth Looking At Closely?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

Ergomed plc to Report Fiscal Year 2022 Results on Mar 21, 2023

High number of new and inexperienced directors

Ergomed plc Announces Board Changes, Effective 3 February 2023

Ergomed plc Announces Executive Changes

Ergomed plc Announces Directorate Changes

Ergomed Announces Two Senior Appointments to its Executive Team

Ergomed Strengthens Executive Management Team

Ergomed Strengthens Executive Management Team

Ergomed plc (LON:ERGO) Shares Could Be 21% Below Their Intrinsic Value Estimate

First half 2022 earnings released: EPS: UK£0.15 (vs UK£0.14 in 1H 2021)

Ergomed plc to Report First Half, 2022 Results on Sep 27, 2022

Investor sentiment improved over the past week

Should You Be Adding Ergomed (LON:ERGO) To Your Watchlist Today?

Why Ergomed plc (LON:ERGO) Could Be Worth Watching

Ergomed plc Appoints Anne Whitaker as Independent Non-Executive Director

Full year 2021 earnings: EPS misses analyst expectations

Ergomed plc, Annual General Meeting, Jun 10, 2022

Consensus EPS estimates increase by 11%

Consensus forecasts updated

Less than half of directors are independent

Now 21% undervalued

Calculating The Fair Value Of Ergomed plc (LON:ERGO)

Full year 2021 earnings: EPS misses analyst expectations

Does Ergomed (LON:ERGO) Deserve A Spot On Your Watchlist?

John Dawson, Cbe Joins the Board of Ergomed plc as Independent Non-Executive Director and Chair of the Audit Committee

Why Ergomed plc (LON:ERGO) Could Be Worth Watching

Ergomed plc to Report Fiscal Year 2021 Results on Mar 29, 2022

Pharmaust Limited Engages Ergomed Clinical Research Ltd to Commence Clinical Trials Testing the Anti-Viral Effects of Monepantel

Ergomed plc (AIM:ERGO) acquired Adamas Consulting Ltd. at an enterprise value of £24.2 million.

Ergomed plc Provides Revenue Guidance for the Year Ended 31 December 2021

Investor sentiment deteriorated over the past week

Calculating The Fair Value Of Ergomed plc (LON:ERGO)

Investor sentiment improved over the past week

I Ran A Stock Scan For Earnings Growth And Ergomed (LON:ERGO) Passed With Ease

First half 2021 earnings released: EPS UK£0.14 (vs UK£0.089 in 1H 2020)

Calculating The Intrinsic Value Of Ergomed plc (LON:ERGO)

Investor sentiment improved over the past week

If You Like EPS Growth Then Check Out Ergomed (LON:ERGO) Before It's Too Late

Getting In Cheap On Ergomed plc (LON:ERGO) Might Be Difficult

Ergomed plc (LON:ERGO) Shares Could Be 31% Above Their Intrinsic Value Estimate

Price target increased to UK£13.65

Non-Executive Director has left the company

Investor sentiment improved over the past week

Do Ergomed's (LON:ERGO) Earnings Warrant Your Attention?

Full year 2020 earnings released

Price target increased to UK£12.70

If You Had Bought Ergomed (LON:ERGO) Stock Five Years Ago, You Could Pocket A 643% Gain Today

New 90-day high: UK£12.45

Ergomed plc to Report Fiscal Year 2020 Results on Mar 23, 2021

Price target raised to UK£11.85

Has Ergomed plc's (LON:ERGO) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

New 90-day high: UK£10.55

Ergomed plc (AIM:ERGO) acquired MedSource Consulting Inc. for $25 million.

Ergomed plc's (LON:ERGO) Intrinsic Value Is Potentially 20% Below Its Share Price

New 90-day high: UK£9.50